UCB Sponsors Data Presentations on Epilepsy and VimpatÃ‚® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology
ATLANTA, April 18, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, will sponsor multiple sets of key epilepsy data at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans from April 21-28. The data comprise several posters examining the use of the antiepileptic drug (AED) Vimpat® (lacosamide) C-V, including updated health-related quality of life analysis from pooled open label extension trials.
"UCB is committed to advancing research to better understand the clinical profile of Vimpat®. The research we will present at AAN encompasses several lacosamide studies that measure patient-reported seizure frequency and health-related quality of life over the long-term," said Dr. James Zackheim, PhD, Senior Medical Director, Central Nervous System Business Unit, UCB, Inc.
Vimpat® is indicated as an add-on therapy for the treatment of partial-onset seizures in adults with epilepsy. The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of Vimpat®-treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia. Additional important safety information for Vimpat® is available at the end of the press release.
Following is a guide to UCB-sponsored posters for Vimpat® and epilepsy being exhibited during AAN. For more information please contact Andrea Levin at 404.483.7329 or Andrea.Levin@ucb.com.
Vimpat® (lacosamide) C-V Posters:
1. Lacosamide as Add-On to Monotherapy in Patients with Partial-Onset Seizures: Interim Results of the Post-Marketing VITOBA Study (VImpaT added to One Baseline AED)
P06.126; Poster Session VI: Thursday, April 26, 7:30 a.